Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8714651 | The Journal of Allergy and Clinical Immunology: In Practice | 2017 | 13 Pages |
Abstract
In patients with moderate-to-severe eosinophilic asthma, intravenous reslizumab 3.0 mg/kg displays favorable long-term safety and sustained long-term efficacy. Initial improvements in lung function and asthma control were maintained for up to 2 years. These findings substantially add to our understanding of the long-term safety and efficacy of anti-IL-5 strategies.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Kevin MD, Joshua MD, Leif MD, John M. MD, Yael MD, Margaret MD, James MD, Mario MD,